We previously reported that many ingenol compounds derived from Euphoria kansui exhibit topoisomerase inhibitory activity. 20-O-ingenolEZ in these compounds exerted inhibitory effects on both topoisomerase II (topo II) activity and cell proliferative activity. Topoisomerase II inhibitors can be divided into the poison and catalytic inhibitor types and 20-O-ingenolEZ is a catalytic inhibitor and inhibits topo IIα through inhibition of ATPase activity, but induces topo II-mediated DNA damage and apoptosis in BLM 
Introduction
Topoisomerase II (topo II) is essential for the survival of proliferating cells, and it is involved in recombination, chromosome condensation, and decatenation of sister chromatids before anaphase of mitosis [1] . In cancer chemotherapy, topo II is a major target for various anticancer drugs. These drugs can be divided into two types based on their mode of action. One type is the topo II poisons, so named because of their severe cytotoxicity resulting from their ability to stabilize enzyme-DNA covalent complexes and activates DNA damage checkpoint [2, 3] . Topo II catalytic inhibitors do not stabilize topo II-DNA covalent complexes. Instead, these compounds block the enzyme before DNA cleavage or at the last step of the catalytic cycle after religation [4, 5] . An example of this latter type of inhibitors is ICRF-193 (bisdioxopiperazine), which blocks the opening of an already closed clamp by inhibiting ATPase activity of the enzyme and preventing DNA decatenation of the replicated chromosomes by it, thus arresting cell proliferation [6, 7] . These catalytic inhibitors inhibit topo II before the transient double-strand breakage step and activate the decatenation checkpoint [8, 9] . The topo II poisons have been developed as anticancer agents for clinical use [10] . However, they function by stabilizing the state in which the enzyme introduced DSBs [11, 12] . Despite their broad anticancer activity, the use of topo II poisons is limited by their narrow therapeutic window, since the damage to healthy cells that divided more rapidly, such as bone marrow cells and the gut lining and tissues is almost inevitable. Thus, new types of potent inhibitors of topo II that induce the DNA decatenation checkpoint are desired [13, 14] .
We previously reported that 20-O-ingenolEZ functions as a catalytic inhibitor and inhibits the ATPase activity of topo IIα and induces G2 arrest of MMT cells [15] . However, treatment of BLM −/− DT40 cells with 20-O-ingenolEZ induces DNA damage signaling and apoptosis [16] . Although the inhibition of cell proliferation through the induction of topo II decatenation checkpoint is weak than that by topo II damage checkpoint [17] [18] [19] , catalytic inhibitors have low DNA truncation toxicity [20, 21] and an inefficient decatenation checkpoint for stem and progenitor cells [22] . Furthermore, the catalytic inhibitor ICRF-193 was showed to be hypersensitive to inhibition of cell proliferation of cancer cells with impaired decatenation checkpoint function and to induce apoptosis of these specific cells [23, 24] . Topo II catalytic inhibitors which induces DNA damage signaling and apoptosis is useful as new types of potent inhibitors of topo II. More studies are required to identify particular cell lines responsive to 20-O-ingenolEZ and ICRF-193. In this study, an assay for detecting topo II poisons or catalytic inhibitors was preformed using a compound structurally distinct but related to 20-O-ingenolEZ. Furthermore, since the specificity of inhibition of the proliferation of various cell lines by similar compounds may not be correlated, the specificity of cell proliferation inhibition by 20-OingenolEZ and ICRF-193 was compared using other mutated cell lines, although the mechanism of inhibition of topo II activities was the same for the two compounds. 
Materials and Methods

Cell Lines and Cell Proliferation
BLM
−/− DT40 cells were provided by RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. BLM −/− DT40 cells were grown in RPMI 1640 medium containing 50 μM of mercaptoethanol, 10% fetal bovine serum (FBS), and 1% chicken serum. Rat testicular tumor (LC540) cells and mouse normal 3T3-Swiss albino (3T3) cells were grown in Minimum Essential Medium (MEM) supplemented with 10% FBS. BT-474 cells were grown in Hybri-Care medium containing 10% FBS. MCF-7 cells were grown in MEM supplemented with 25 μM insulin, 1 μM sodium pyruvate, 10% nonessential amino acids, and 10% FBS. The cells were then transplanted on microculture plates. The diterpene compound 20-O-(2(E),4(Z)-decadienoyl) ingenol (20-O-ingenolEZ) was dissolved in dimethyl sulfoxide. After appropriate dilution, the compound was added to 100 μl of medium and the cells were incubated for 24 h at 37˚C in 95% air and 5% CO 2 . Cell growth in the presence or absence of the compound was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay [25] (Roche Applied Science). The optical density of each well was measured at 620 nm using a plate reader (Amersham).
Topo II-Mediated Supercoiled pBR322 Relaxation
The activity of the compounds on relaxation induced by DNA topo IIα (human recombinant in E. coli, Topo GEN, Inc. USA) was determined by measuring the conversion of supercoiled pBR322 plasmid DNA (TOYOBO, Tokyo) to its relaxed form. The reaction mixture contained 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM MgCl 2 , 500 μM DTT, 30 μg/ml BSA, 5 mM ATP, 90 ng pBR322, 1 U of enzyme and different concentrations of the compounds in a total volume of 20 μl. After incubation for 9.5 min at 37˚C, the mixture was subjected to electrophoresis on a 1% agarose gel. After electrophoresis, the gel was stained with ethidium bromide and visualized under UV light.
ATPase Assay
Hydrolysis catalyzed by human topo IIα was examined by measuring the liberating of phosphate, as described by Cogan et al. [26] . The reaction mixture contained 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM ATP, 500 μM DTT, 30 μg/ml BSA, 180 ng pBR322 and 1 U human topo IIα. After 9.5 min, 200 μl of reagent containing 0.23 mg/ml malachite green, 10.6 mg/ml ammonium molybdate, 6% H 2 SO 4 , and 0.02% Tween 20 was added, and the mixture was incubated for 5 min at room temperature for color development. Absorbance was measured at 620 nm using a microplate reader.
Western Blotting
BLM −/− DT40 cells were cultured for 24 h in the presence of 200 μM 20-O-ingenolEZ, 5 μM ICRF-193, or 0.9 μM adriamycin, washed in phosphate-buffered saline (PBS), suspended in a lysis buffer [20 mM HEPES (pH 7.8), 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% Triton-X100, 20% glycerol, and 1 mM DTT supplemented with protease inhibitors] and lysed. After centrifugation at 2,100 rpm for 4 min, the precipitate was resuspended in lysis buffer containing 500 mM NaCl instead of 10 mM NaCl and placed on ice for 30 min. The suspension was centrifuged at 15,000 rpm for 15 min at 4˚C. Twenty μg of nuclear protein was subjected to electrophoresis on 15% SDS-polyacrylamide gels, and transferred to a polyvinylidene difluoride membrane. Blots were prepared using anti-γ-H2AX antibody (Millipore, Billerica, MA, USA) followed by detection with an enhanced chemiluminescence system. 193, or 0.9 μM adriamycin. Cells were washed three times with PBS for 5 min. Apoptotic cells and nuclei were stained for 10 min at room temperature with 4,6-diamino-2-phenyl indole (DAPI, at 1 μg/ml PBS) and detected by fluorescence microscopy. 
Effects on the Proliferation of Cancer Cells
To [11] . The proliferation of BLM −/− DT40 cells was not inhibited by 20-O-ingenolEZ at concentrations of 2 -60 μM, but was completely and immediately inhibited at concentrations higher than 100 μM (Figure 3(a) ). (Figure 4(b) ). An ICRF-193 concentration of 200 μM weakly inhibited both human breast cancer cell lines (Figure 4(b) ). 
Effects of 20-O-IngenolEZ on the Phosphorylation of H2AX
We also observed the appearance of phosphorylated H2AX (γ-H2AX), which serves as a marker of DNA double strand breaks (DSBs) [27] , using BLM −/− DT40 cells. Adriamycin is known to stabilize topo II DNAcovalent complexes, and DNA damage is induced through numerous signaling pathways. γ-H2AX was visualized as a band stained with anti-γ-H2AX in the nuclei of adriamycin-treated BLM −/− DT40 cells ( Figure 5, lane 3) . We observed a similar induction of DSBs in 20-O-ingenol-EZ-and ICRF-193-treated BLM −/− DT40 cells ( Figure 5,  lanes 2 and 4) .
Effects of 20-O-IngenolEZ and ICRF-193 on Apoptosis
Since both 24 h of treatment with 0.9 μM adriamycin, BLM −/− DT40 cells were stained with DAPI (Figure 6(a) ), and apoptosis was found to be induced in approximately 60% of cells (Figure 6(b) ). 20-O-ingenolEZ-treated BLM −/− DT40 cells also exhibited morphological characteristics of apoptosis similar to those observed in adriamycin-treated BLM −/− DT40 cells (Figure 6 ). ICRF-193-treated BLM −/− DT40 cells were also apoptotic (Figure 6 ).
Discussion
We ICRF-193 treatment delayed the G2/M transition of the cell cycle [28, 29] and the nature of this G2 delay has been proposed as a "decatenation checkpoint" where cells monitor chromatide catenation status after DNA replication and inhibit progression to mitosis until decatenation of the chromatids by topo II is accurate [30] . Many studies have suggested that the decatenation checkpoint is distinct from the DNA damage checkpoint. [16, 31] . However, we have demonstrated that 20-O-ingenolEZ is a novel topo II catalytic inhibitor that induces DNA damage signaling in BLM −/− DT40 cells. This inhibition induces the phosphorylation of H2AX in response to agents that introduce topo II-mediated DNA damage signaling. ICRF-193 has been extensively analyzed as a topo II catalytic inhibitor in studies of the functions of topo II [2] [3] [4] [5] [28] [29] [30] , and several recent observations have suggested that ICRF-193 may induce DNA damage [20, 32, 33] . Therefore, we studied damage signaling induced by ICRF-193, which inhibited the proliferation of the BLM −/− DT40 cells in this studies. We also observed that the two types of topo II catalytic inhibitors activated DNA damage signaling and apoptosis in BLM −/− DT40 cells. With regard to the mechanism of induction of damage signaling and apoptosis, topo II poison such as VP-16 (etoposide) has been shown to induce preferential degradation of topo IIβ through a proteasome pathway, which is responsible for the exposure of topo IIβ-mediated DSBs [34] . Furthermore, it has been revealed that ICRF-193 can also arrest transcription and triggers proteosomal degradation of topo IIβ. It is believed that in the presence of ICRF-193 and ATP, topo IIβ is trapped as a closed circular clamp on DNA and the topo II circular clamp triggers 26S proteosome-dependent degradation of topo IIβ [35] . DSBs induced by proteasome degradation can be repaired by homologous recombination and /or by nonhomologous endojoining [17] . If [16] . Therefore, we studied the effects of 20-O-ingenol-EZ and ICRF-193 on proliferation on cell lines with mutated DNA repair-related genes that function together with BLM. BLM forms a complex with the recombination protein RAD51C. The interaction between BLM and RAD51C provides the first direct molecular link in the pathway for recombinational repair in human cells [37] [38] [39] . In the MCF-7 breast cancer cell line, RAD51C-ATXN7 fusion gene breakpoints have been confirmed [40, 41] . 20-O-ingenolEZ showed hypersensitivity to inhibition of cell proliferation of MCF-7 cells compared with that of BT-474 breast cancer cell, which overexpressed ErbB mRNA [42] . In a recent study, RAD51C was confirmed as a breast and ovarian cancer susceptibility gene [43] . We revealed that a catalytic inhibitor inducing a decatenation checkpoint, 20-O-ingenolEZ, inhibited the proliferation of BLM −/− DT40 [16] and MCF-7 cells with mutated DNA repair-related gene; it was hypersensitive to these cells compared to BT-474 breast cancer cells. Thus, compounds that target the induction of the decatenation checkpoint may selectively target repair-deficient cancer cells such as RAD51C. Further drug discovery efforts relating to ingenol compounds are warranted and such drugs could potentially be developed as anticancer therapies. 
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